Trethera is leveraging new insights into metabolic pathways to advance novel treatment strategies for solid tumors and autoimmune diseases.
Cancer cells generate the precursors for DNA replication and repair differently than healthy cells. Trethera’s lead product candidate, TRE-515, exploits this difference by inhibiting the rate-limiting enzyme in the salvage pathway of nucleotide biosynthesis. This therapy is designed to be effective in certain solid tumors with underlying metabolic sensitivity to the mechanism, or in combination with other therapeutics to enhance efficacy or overcome resistance.
The close links between the immune system and cancer have become better understood over the past decade. Many drugs, like Roche’s Rituxan, treat both autoimmune disorders and cancers. Autoimmune disease occurs when the immune system mistakenly attacks normal tissue to cause diseases like multiple sclerosis or lupus. The enzyme which the TRE-515 drug inhibits, dCK, may have a role in the immune activation which causes these diseases.
13547 Ventura Boulevard, Suite 363
Sherman Oaks, CA 91423